The classical-baseline gate
No advantage claim raises a verdict without a named benchmark, a problem size and a classical comparator. Missing any → it is flagged needs-baseline and cannot reach Proceed. The software enforces it.
Home / Solutions
Solutions
One evidence engine.
Four decisions it defends.
Every Veriqa engagement runs the same discipline — claims graded against a classical baseline, every line sourced, nothing reaching a Proceed verdict without a comparator. What changes is the decision in front of you. Pick the one you own.
01 · Choose your decision
Four fronts, one referee.
Each solution is a first-class engagement with its own inputs, outputs and buyer — built on the same neutral evidence layer.
01
Investors & corp-dev
Diligence quantum startups, public-company narratives and M&A targets on the evidence — hype-risk scored, baselines demanded, a Proceed / Monitor / Require-further-diligence memo you can put in front of an IC.
Explore investor diligence →02
Security / PQC
Turn a cryptographic inventory into a phased post-quantum migration plan mapped to NIST FIPS 203/204/205, prioritised by harvest-now-decrypt-later exposure and data shelf-life.
Explore PQC migration →03
Pharma & R&D
Separate AI-assisted design, classical simulation and selective quantum refinement into a conservative, patent-ready evidence package — wet-lab gaps flagged, no overclaiming.
Explore molecular-design evidence →04
Defense & dual-use
Map quantum sensing, navigation (PNT), secure comms and dual-use programs to evidence-graded readiness and realistic procurement paths — TRL-honest, hype-free.
Explore defense diligence →02 · Compare at a glance
The four solutions on one screen.
Same engine, four buyers, four decision shapes. The matrix below puts inputs, outputs, who buys, when to engage, scope, standards and adjacent workflows side by side — so you don't have to read four pages to know which is yours.
| Solution | Inputs | Outputs | Who buys | When to engage | Typical scope | Standards / frameworks | Adjacent workflow |
|---|---|---|---|---|---|---|---|
| Investors & corp-dev | Company memo, pitch deck, papers, patents, public roadmap | Verdict memo + evidence table + IP & team check | VC IC, corp-dev, growth equity, family office | Pre-IC; quantum thesis you must defend | 1–2 weeks · single target · brief or pilot | arXiv, patent corpora, public roadmaps | IC memo, board deck, investment committee |
| Security / PQC | Cryptographic inventory, network diagrams, data-shelf-life model | Phased migration plan + HNDL-prioritized roadmap | CISO, head of crypto, regulated-industry sec lead | Migration clock running; FIPS 203/204/205 mandate | 3–6 weeks · org-wide inventory · pilot or workspace | NIST FIPS 203/204/205, CNSA 2.0, NSM-10 | SOC 2 audit prep, crypto-agility roadmap, GRC tooling |
| Pharma & R&D | Computational claim, pre-print, vendor materials, simulation logs | Patent-ready evidence package + classical comparator | R&D director, head of computational chemistry, CSO | Before synthesis ramp; before IND-enabling investment | 2–4 weeks · one program · brief or pilot | FEP+ / DFT / MD baselines, TRL, CASF | IND-enabling package, patent filing support |
| Defense & dual-use | Vendor materials, public DoD program docs, open-source claims | TRL-honest readiness memo + classical comparator | Program manager, PEO, defense procurement, primes | Before procurement commitment; readiness review | 2–6 weeks · unclassified open sources only | TRL 1–9, NIST PQC, CNSA 2.0, NSM-10 | Program review, capability assessment, RFP scoping |
Same engine across all four — what changes is the decision in front of you. See an illustrative sample brief for each vertical →
03 · Pick yours
Three questions, one starting point.
If you read the matrix and still aren't sure, answer these three.
-
What kind of decision are you defending?
An investment or acquisition → Investors & corp-dev. A migration deadline or cryptographic risk → Security / PQC. An R&D investment or synthesis ramp → Pharma & R&D. A procurement, program, or capability assessment → Defense & dual-use.
-
Do you need a one-shot brief, or a recurring workspace?
Most engagements start as a fixed-price brief. If the decision recurs (a portfolio, an inventory, an ongoing program) it converts into a pilot, then a workspace. See pricing for tiers.
-
Still on the fence?
Send the decision in plain English. We respond with scope and a fixed price usually within two business days. Request a brief →
03 · Not sure which fits?
Start from the decision, not the technology.
Deciding whether to back, buy or partner with a quantum company? That is investor & corp-dev diligence — start there.
On the hook for cryptographic risk and a migration clock? That is the PQC / security track.
Evaluating a molecular-design or simulation claim? Pharma & R&D evidence packaging.
Assessing a sensing, PNT, comms or dual-use program? Defense & dual-use readiness.
Still unsure? Send us the company, claim, paper or program and we will tell you which engagement fits — and scope it.
What you get back
- A Proceed / Monitor / Require-further-diligence verdict
- Three scores: maturity, urgency, hype-risk
- An evidence table — every claim sourced & graded
- Missing-evidence flags and a validation plan
- An auditable, machine-readable export
Bring us the decision you have to defend.
Tell us the company, claim, paper or program. We respond with scope and a fixed price usually within two business days.